Wiley Matthew T. — SEC insider filings

SEC reporting owner CIK 1759703. 21 insider filings on record with FilingPulse; latest filed 2026-09-29.

Transaction summary — filings shown

Covers all 21 filings on record, filed 2020-10-02 to 2026-09-29. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Definium Therapeutics, Inc. (DFTX)Chief Commercial Officer7—2 legs · 5,964 sh · $242,3585
BioXcel Therapeutics, Inc. (BTAI)—8—4 legs · 7,739 sh · $6,56212
VYNE Therapeutics Inc. (VYNE)Chief Commercial Officer6——7

Insider filings — Wiley Matthew T.

FiledFormIssuerReported transactionsSource
2026-09-294Definium Therapeutics, Inc. (DFTX)Sale (S): 3,097 @ $36.57EDGAR
2026-09-144Definium Therapeutics, Inc. (DFTX)Grant/award (A): 125,000 @ $0EDGAR
2026-08-124Definium Therapeutics, Inc. (DFTX)Grant/award (A): 62,500 @ $0EDGAR
2026-06-264Definium Therapeutics, Inc. (DFTX)Sale (S): 2,867 @ $45.03EDGAR
2026-06-224Definium Therapeutics, Inc. (DFTX)Grant/award (A): 62,500 @ $0EDGAR
2026-02-054Definium Therapeutics, Inc. (DFTX)Grant/award (A): 115,000 @ $0EDGAR
2025-04-014BioXcel Therapeutics, Inc. (BTAI)Grant/award (A): 1,875 (derivative) @ $0EDGAR
2025-03-184Mind Medicine (MindMed) Inc. (MNMD)Grant/award (A): 350,000 (derivative) @ $0EDGAR
2024-10-034BioXcel Therapeutics, Inc. (BTAI)Grant/award (A): 21,250 · Sale (S): 6,272 @ $0.55EDGAR
2024-09-174/ABioXcel Therapeutics, Inc. (BTAI)Option exercise (M): 750 (derivative) @ $0EDGAR
2024-09-174BioXcel Therapeutics, Inc. (BTAI)Option exercise (M): 750 · Sale (S): 215 @ $0.69 · Option exercise (M): 750 (derivative) @ $0EDGAR
2024-06-184BioXcel Therapeutics, Inc. (BTAI)Option exercise (M): 750 · Sale (S): 244 @ $1.26 · Option exercise (M): 750 (derivative) @ $0EDGAR
2024-04-084BioXcel Therapeutics, Inc. (BTAI)Option exercise (M): 3,000 · Sale (S): 1,008 @ $2.64 · Option exercise (M): 3,000 (derivative) @ $0EDGAR
2023-03-164BioXcel Therapeutics, Inc. (BTAI)Grant/award (A): 12,000 (derivative) @ $0 · Grant/award (A): 36,000 (derivative) @ $0EDGAR
2022-01-194BioXcel Therapeutics, Inc. (BTAI)Grant/award (A): 85,000 (derivative) @ $0EDGAR
2021-07-024VYNE Therapeutics Inc. (VYNE)Tax withholding (F): 5,151 @ $3.51EDGAR
2021-04-024VYNE Therapeutics Inc. (VYNE)Tax withholding (F): 2,573 @ $6.84EDGAR
2021-02-244VYNE Therapeutics Inc. (VYNE)Grant/award (A): 27,675 @ $0 · Grant/award (A): 64,575 (derivative) @ $0EDGAR
2021-01-054VYNE Therapeutics Inc. (VYNE)Tax withholding (F): 1,541 @ $1.58EDGAR
2020-12-024VYNE Therapeutics Inc. (VYNE)Grant/award (A): 7,838 @ $1.45EDGAR
2020-10-024VYNE Therapeutics Inc. (VYNE)Tax withholding (F): 1,541 @ $1.66EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-09-28 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1759703 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs